COYA 201
Undisclosed Inflammatory Indications
PreclinicalPlatform Research
Key Facts
Indication
Undisclosed Inflammatory Indications
Phase
Preclinical
Status
Platform Research
Company
About Coya Therapeutics
Coya Therapeutics' mission is to develop novel Treg-enhancing therapies to address chronic inflammatory diseases driven by immune dysfunction. The company has achieved key milestones, including Health Canada CTA acceptance for a Phase 2 ALS trial and U.S. FDA IND clearance for Frontotemporal Dementia for its lead candidate COYA 302. Its strategy leverages a diversified platform of biologics, exosomes, and cell therapies to target multiple indications and patient populations. Recent private financing provides capital to advance its clinical programs.
View full company profileTherapeutic Areas
Other Undisclosed Inflammatory Indications Drugs
| Drug | Company | Phase |
|---|---|---|
| ANB101 | AnaptysBio | Phase 1 |